It's The Lancet Oncology day for Rad Onc GU! Our consensus on SBRT for Oligomets RCC is finally out! Thanks to all the participants! 🔥🔥🔥🌟🌟🌟
Delphi consensus on stereotactic ablative radiotherapy for oligometast... sciencedirect.com/science/articl…

OLIGOPELVIS and the “All You Can Eat” Strategy for Oligorecurrent Nodal Prostate Cancer: Are We Already Full? ⁦Piet Ost⁩ ⁦Shankar Siva⁩ ⁦Supiot Stéphane⁩ ⁦Paul Sargos⁩ sciencedirect.com/science/articl…

Pierre Blanchard, MD Tony Felefly Advanced Prostate Cancer Consensus Conference To benefit from ART, you would have to have local-only disease. Pts with v high risk disease at surgery must have significant risk of micrometastases

PSMA has 80-90% NPV but poor sensitivity for pelvic lymph nodes - cannot replace staging extended PLND. Plus new data that ePLND reduces distant metastases -Jochen Walz #apccc24

When Oligometastatix (aka me) and Pelvix (aka Vedang Murthy) share a 3h train ride home from #APCCC24 , new trials are born! Be ready for us #APCCC30 ! Thanks again silke gillessen and aurelius omlin for having us.

Pierre Blanchard, MD Advanced Prostate Cancer Consensus Conference Daniel E Spratt Furthermore, I find it hard to believe that adjuvant RT substantially improves PCa specific mortality without any significant reduction in metastatic disease

Pierre Blanchard, MD Advanced Prostate Cancer Consensus Conference Daniel E Spratt highlighted the PCa specific mortality data from the RADICALS-RT update. This result is based on only 17 events, so I am wary of over-interpreting the apparent benefit for adjuvant RT

Daniel E Spratt Pierre Blanchard, MD Advanced Prostate Cancer Consensus Conference Thank you for your thoughtful comments Daniel E Spratt On current evidence, like you, I am not a fan of ART. It will be interesting to see an update of the ARTISTIC meta-analysis in due course.

#APCCC2024 Advanced Prostate Cancer Consensus Conference 👉 outstanding talk by the super star Vedang Murthy from Tata Memorial Hospital , Mumbai 👉challenges faced by oncology docs in India & solutions👉Simplify care, improve access, & remarkable advances in telemedicine 👇OncoAlert silke gillessen NationalCancerGrid

Vedang Murthy at #APCCC24 for #prostatecancer !

Inequalities are everywhere, what are we going to do about it?

Tata Memorial Hospital 🇮🇳showing the way with many innovative solutions!

Advanced Prostate Cancer Consensus Conference SOGO TMC Radiation Oncology ACTREC-TMC

Thank you Prof Parker Chris Parker and Deep Chakrabarti. As we have shown in our NMA, we firmly believe that ADT + ARPI + Primary RT should be the SOC Rx for de novo low volume mHSPC. Thank you European Urology for considering our paper w/ this supportive editorial.

Experts still favor metastasis directed therapy for oligometastatic #prostatecancer although enrollment in clinical trials is encouraged.

Thanks tombal for the shout out to the oligoPresto trial (part of PEACE 6) that is now 460/550 pts accrued.

⚡️ NECTIN4 Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer

#BladderCancer #Immunology Markus Eckstein
Journal of Clinical Oncology

ascopubs.org/doi/10.1200/JC…

Please join us during #ESTRO24 where the STORM consortium will provide the first oncological results for nodal recurrences. Thomas Zilli

• Testosterone recovery after stopping ADT – Who is at risk for long-term non-recovery?- Pierre Blanchard, MD

Advanced Prostate Cancer Consensus Conference silke gillessen OncoAlert Thomas Zilli Daniel Castellano Piet Ost Dra. María Natalia Gandur Quiroga Deborah Mukherji Neeraj Agarwal, MD, FASCO Rana McKay Michael Hofman Declan Murphy Neha Vapiwala

On the train in a trial though 😉. Thunder trial started recruitment in December 23 and 40 patients recruited in only 3-4 months.

Check out the Cheat Sheet on the treatment of #ErectileDysfunction . The management algorithm outlines modifiable factors and current therapies for successful treatment. While ED can't always be cured, effective management is possible.

#EAUguidelines

uroweb.org/guidelines/sex…

How to manage patients with PSA persistence following radical prostatectomy? Presentation by Derya Tilki, MD Martini-Klinik am UKE. #APCCC24 written coverage by Zach Klaassen Georgia Cancer Center > bit.ly/49Q5p3z Advanced Prostate Cancer Consensus Conference

🩺 On European Urology - Oligometastatic Bladder Cancer: Defining a Novel Entity

#BladderCancer Chris Labaki Toni Choueiri, MD Eddy Saad joaquim bellmunt

europeanurology.com/article/S0302-…

How to manage patients with PSA persistence following radical prostatectomy? Fantastic insights from Derya Tilki, MD at #Apccc24
⭕️ Risk stratification according to pathologic features, PSA levels/kinetics, and genomic classifier may aid in personalization of treatment.
Advanced Prostate Cancer Consensus Conference…